[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

September 17, 2020
Original Investigation

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3938

This cohort study evaluates the association of coffee consumption with disease progression and death in patients with advanced or metastatic colorectal cancer.

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3927

This randomized clinical trial evaluates the efficacy and safety of nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer.

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

Abstract Full Text
has audio
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.4232

This cohort study uses data from the National Cancer Database to assess the association between adjuvant chemotherapy and survival in patients with node-negative early-stage non–small cell lung cancer (NSCLC) with vs without high-risk pathologic features.

Brief Report

Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3697

This cross-sectional survey study examines whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians, and if so, whether patient-level barriers are associated with racial differences.

Research Letter

Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic

Abstract Full Text
free access
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.4408

This prospective observational study assesses changes in treatment plans for patients with lung cancer and qualifies the types of changes observed as a direct result of the coronavirus disease 2019 pandemic.

Viewpoint

Efficacy, Improved Quality of Life, and Cost-effectiveness of Partial Breast Irradiation: A Triple-Threat Approach

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.0795

This Viewpoint provides an evaluation of partial breast irradiation as an alternative to standard and hypofractionated whole-breast irradiation in terms of its ability to reduce duration of treatment and provide equivalent outcomes, comparable or reduced adverse effects, and cost-effectiveness

Invited Commentary

Coffee and Colorectal Cancer: Is Improved Survival a “Perk of Coffee Drinking?

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3313
Comment & Response

The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3703

The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply

Abstract Full Text
JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3706
September 10, 2020
Original Investigation

Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment

Abstract Full Text
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.3537

This cohort study uses data from an existing cohort of patients undergoing resection of pancreatic cancer to assess the overall survival of patients treated with neoadjuvant FOLFIRINOX after surgery for pancreatic ductal adenocarcinoma.

Brief Report

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.3689

This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.

JAMA Oncology Clinical Challenge

Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases

Abstract Full Text
has active quiz
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.2693

A 48-year-old man with a history of rectal adenocarcinoma and multiple lung metastases presents with a 1-cm posterior subglottic lesion of unclear origin found on restaging scans. What is your diagnosis?

Viewpoint

Hospital Deaths a Poor Quality Metric for Patients With Cancer

Abstract Full Text
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.1043

This Viewpoint explores whether hospital death rates should still be considered an appropriate quality metric when it comes to the care of patients with cancer.

Poetry and Oncology

Walking the Gauntlet

Abstract Full Text
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.4346
Comment & Response

Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer

Abstract Full Text
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.3389

Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.3400
Correction

Error in Author Name

Abstract Full Text
free access
JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.4696
September 3, 2020
Original Investigation

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.3370

This phase 3, randomized, controlled, partially blinded interventional study evaluates the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced gastric/gastroesophageal junction cancer with PD-L1 combined positive score ≥1.

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.3524

This phase 2 randomized clinical trial compares the efficacy of eribulin plus pembrolizumab vs eribulin alone in hormone receptor–positive, ERBB2-negative metastatic breast cancer.

Research Letter

Use of Natural Language Processing to Assess Frequency of Functional Status Documentation for Patients Newly Diagnosed With Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.2708

This cross-sectional study applies natural language processing to electronic health records from a large health care delivery system to examine performance status documentation among patients newly diagnosed with colorectal cancer.

Viewpoint

The Day After COVID-19—Time to Rethink Oncology Clinical Research

Abstract Full Text
free access
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.4240

This Viewpoint discusses how the COVID-19 pandemic may reshape clinical practice and clinical research as new technologies are incorporated and old practices are revisited and revamped.

Editorial

Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.2436
Comment & Response

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.3386

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection—Reply

Abstract Full Text
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.3397
×